grazoprevir - CAS 1350514-68-9
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C38H50N6O9S
Molecular Weight:
766.901
COA:
Inquire
Description:
Grazoprevir is a hepatitis C virus protease inhibitor developed for the treatment of hepatitis C. It suppresses NS3 and NS4A, which play a role in the virus splitting its polyprotein into the functional virus proteins. Grazoprevir is often used in combination with elbasvir or ribavirin.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
hepatitis C virus protease inhibitor
Related CAS:
1350514-68-9 (free); 1350462-55-3 (hydrate)
Appearance:
Solid powder
Synonyms:
(33R,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide; MK-5172; MK 5172; MK5172; Grazoprevir trade name: Zepatier‎
MSDS:
Inquire
Application:
the treatment of hepatitis C
InChIKey:
OBMNJSNZOWALQB-NCQNOWPTSA-N
InChI:
1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1
Canonical SMILES:
O=C([C@H]1N2C([C@H](C(C)(C)C)NC(O[C@]3([H])C[C@@]3([H])CCCCCC4=NC5=CC=C(OC)C=C5N=C4O[C@](C2)([H])C1)=O)=O)N[C@@]6(C(NS(=O)(C7CC7)=O)=O)[C@H](C=C)C6
Current Developer:
MSD
1.Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Rockstroh JK1, Nelson M2, Katlama C3, Lalezari J4, Mallolas J5, Bloch M6, Matthews GV7, Saag MS8, Zamor PJ9, Orkin C10, Gress J11, Klopfer S11, Shaughnessy M11, Wahl J11, Nguyen BY11, Barr E11, Platt HL11, Robertson MN11, Sulkowski M12. Lancet HIV. 2015 Aug;2(8):e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9.
BACKGROUND: Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality in patients with HIV-1. The C-EDGE CO-INFECTION study assessed the efficacy, safety, and tolerability of grazoprevir (MK-5172) plus elbasvir (MK-8742) in patients with HCV and HIV co-infection.
2.Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172.
Soumana DI1, Kurt Yilmaz N1, Prachanronarong KL1, Aydin C1, Ali A1, Schiffer CA1. ACS Chem Biol. 2016 Apr 15;11(4):900-9. doi: 10.1021/acschembio.5b00647. Epub 2016 Jan 6.
Recent advances in direct-acting antivirals against Hepatitis C Virus (HCV) have led to the development of potent inhibitors, including MK-5172, that target the viral NS3/4A protease with relatively low susceptibility to resistance. MK-5172 has a P2-P4 macrocycle and a unique binding mode among current protease inhibitors where the P2 quinoxaline packs against the catalytic residues H57 and D81. However, the effect of macrocyclization on this binding mode is not clear, as is the relation between macrocyclization, thermodynamic stabilization, and susceptibility to the resistance mutation A156T. We have determined high-resolution crystal structures of linear and P1-P3 macrocyclic analogs of MK-5172 bound to WT and A156T protease and compared these structures, their molecular dynamics, and experimental binding thermodynamics to the parent compound. We find that the "unique" binding mode of MK-5172 is conserved even when the P2-P4 macrocycle is removed or replaced with a P1-P3 macrocycle.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 1350514-68-9 grazoprevir

Quick Inquiry

Verification code

Featured Items